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Naive CD4+ T cells can differentiate into distinct helper T cell subsets, 
including TH1, TH2 and TH17 cells, as well as Foxp3+ regulatory T 
cells (Treg cells)1,2. The TH17 cell and Treg cell subsets have emerged 
as major participants in autoimmunity. TH17 cells represent a pro-
inflammatory subset that can contribute to autoimmunity and tissue 
damage. In contrast, Treg cells are immunosuppressive and prevent 
autoimmunity. The developmental pathways for TH17 cells and Treg 
cells are reciprocally interconnected, and there is plasticity between 
the TH17 cell lineage and Treg cell lineage3–8. Thus, understanding 
the mechanism that control the balance of immunosuppressive Treg 
cells and inflammatory TH17 cells would help in the development of 
therapeutics for intervention during system failures in autoimmunity 
and chronic inflammation. The cytokine TGF-β drives the conversion 
of naive T cells into Treg cells, while TGF-β, together with pro-inflam-
matory cytokines, including IL-6 and IL-21, differentiates T cells into 
TH17 cells2. Mechanistically, TGF-β alone can activate its downstream 
transcription factors Smad2 and Smad3 to induce expression of the 
transcription factor Foxp3, which is essential for the generation of 
Treg cells. In contrast, IL-6 activates the cascade of the kinase JAK 
and transcription factors STAT3 and STAT5 to induce expression of 
the TH17 cell–defining transcriptional factor RORγt critical for IL-
17 expression. Notably, TGF-β alone induces the expression of both 
Foxp3 and RORγt but not that of IL-17 (ref. 4), which indicates that 
some as-yet-unknown effectors downstream of TGF-β–IL-6 signaling 
function to coordinate the transcriptional activities of Foxp3 and 
RORγt. The transcriptional coactivator TAZ (‘transcriptional coac-
tivator with postsynaptic density 65–discs large–zonula occludens 
1–binding (PDZ) motif ’) has pivotal roles in the differentiation of 
mesenchymal stem cells, organ-size control and cancer develop-
ment9–12. In response to TGF-β, TAZ promotes the accumulation of 
Smad proteins in the nucleus and their activation13,14. TAZ and its 
paralog, YAP (‘Yes (proto-oncogene product)-associated protein’), are 
regulated mainly by the Hippo tumor-suppressor pathway15–19. The 
Ste20 (mitogen-activated protein kinase kinase kinase kinase)-like 
kinases MST1 and MST2 (collectively called ‘MST1/2’ here) are key 
components of the mammalian Hippo signaling pathway, along with 
the scaffolding protein WW45, kinases of the NDR family (NDR1, 
NDR2, LATS1 and LATS2), and the adaptor MOB1. MST1/2 phos-
phorylates and activates LATS1–LATS2–MOB1, which then phos-
phorylate their downstream effectors YAP and TAZ. Phosphorylated 
TAZ (or YAP) is either degraded or is sequestered in the cytoplasm by 
the adaptor 14-3-3 (ref. 20). When the Hippo pathway is switched off, 
TAZ (or YAP) translocates to the nucleus and forms a functional tran-
scriptional complex with transcription factors of the TEAD (‘TEA-
ATTS DNA–binding domain’) family (TEAD1–TEAD4) to turn on 
pro-proliferative genes. Although the role of the Hippo signaling 
cascade in cell-growth control has been studied extensively, it is less 
well appreciated that MST1 deficiency in humans and mice results 
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The transcriptional coactivator TAZ regulates 
reciprocal differentiation of TH17 cells and Treg cells
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An imbalance in the lineages of immunosuppressive regulatory T cells (Treg cells) and the inflammatory TH17 subset of helper 
T cells leads to the development of autoimmune and/or inflammatory disease. Here we found that TAZ, a coactivator of TEAD 
transcription factors of Hippo signaling, was expressed under TH17 cell–inducing conditions and was required for TH17 
differentiation and TH17 cell–mediated inflammatory diseases. TAZ was a critical co-activator of the TH17-defining transcription 
factor RORγt. In addition, TAZ attenuated Treg cell development by decreasing acetylation of the Treg cell master regulator Foxp3 
mediated by the histone acetyltransferase Tip60, which targeted Foxp3 for proteasomal degradation. In contrast, under Treg 
cell–skewing conditions, TEAD1 expression and sequestration of TAZ from the transcription factors RORγt and Foxp3 promoted 
Treg cell differentiation. Furthermore, deficiency in TAZ or overexpression of TEAD1 induced Treg cell differentiation, whereas 
expression of a transgene encoding TAZ or activation of TAZ directed TH17 cell differentiation. Our results demonstrate a pivotal 
role for TAZ in regulating the differentiation of Treg cells and TH17 cells.
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in a complex combined immunodeficiency syndrome with autoim-
mune manifestations21–23. Studies have indicated that this pathway 
regulates the migration and activation of T cells and is also essential 
in innate immunity and cancer immunity24–42. However, the role of 
Hippo signaling in T cell differentiation is as yet largely unexplored. 
Here we found that TAZ, but not YAP, was induced exclusively in the 
TH17 cell lineage and that TAZ was required for TH17 differentiation 
and TH17 cell–mediated inflammatory diseases. Our results identified 
TAZ as a critical co-activator of the TH17 cell–defining transcriptional 
factor RORγt. In addition, TAZ attenuated Treg cell development by 
decreasing acetylation of the Treg cell master regulator Foxp3 medi-
ated by the histone acetyltransferase Tip60, and targeted Foxp3 for 
proteasomal degradation. In contrast, Treg cell–skewing triggered high 
expression of TEAD1, which sequestered TAZ from RORγt, Tip60 and 
Foxp3 to promote Treg cell differentiation. Thus, TEAD functions as 
an antagonist of TAZ directed against TH17 differentiation. Notably, 
TAZ deficiency induced Treg cell differentiation, whereas expression 
of a transgene encoding TAZ or activation of TAZ directed TH17 cell 
differentiation. Our results demonstrate that TAZ functions as a cell-
fate switch between the immunosuppressive Treg cell lineage and the 
inflammatory TH17 cell lineage.
RESULTS
Substantial enrichment for TAZ in the TH17 cell subset
To explore the role of MST1/2 in the activation and differentiation 
of T cells, we generated mice with conditional deletion of MST1/2 in 
activated T cells by crossing mice homozygous for loxP-flanked alleles 
encoding MST1 and MST2 (Mst1fl/flMst2fl/fl) with mice with trans-
genic expression of Cre recombinase from the gene encoding OX40 
(Tnfrsf4; called ‘Ox40’ here), a marker of activated T cells (Ox40-Cre). 
Mst1fl/flMst2fl/flOx40-Cre mice exhibited normal T cell development 
in the thymus (Supplementary Fig. 1a) and normal numbers of T 
cells in peripheral lymphoid tissues, but slightly more effector-mem-
ory T cells in the spleen than those of their Mst1fl/flMst2fl/fl littermates 
(Supplementary Fig. 1b–d). Next, we immunized Mst1fl/flMst2fl/fl 
Ox40-Cre mice and their Mst1fl/flMst2fl/fl littermates with keyhole 
limpet hemocyanin (KLH) in complete Freund’s adjuvant. After 
1 week, a comprehensive analysis of the lymphocytes from draining 
lymph nodes by mass cytometry was performed. Notably, knock-
out of MST1/2 resulted in a substantial increase in the frequency 
of TH17 cells and a modest decrease in the frequency of Treg cells 
(Fig. 1a). Also notably, real-time PCR analysis of genes encoding the 
components of the Hippo pathway showed that Taz mRNA, but not 
Yap1 mRNA, was robustly induced in both Treg cells and TH17 cells 
but underwent the greatest induction in TH17 cells (Fig. 1b). Tead1 
mRNA was much more abundant in Treg cells than in TH0 cells but 
was undetectable in other subsets analyzed (Fig. 1b). The increased 
expression of TAZ in TH17 cells and Treg cells was confirmed by 
immunoblot analysis (Fig. 1c). Furthermore, TAZ-deficient mice 
(generated by crossing of Tazfl/fl mice with mice expressing Cre from 
the gene encoding the T cell–specific tyrosine kinase Lck (Lck-Cre): 
Tazfl/flLck-Cre mice) immunized with KLH exhibited a larger TH17 
population and fewer Treg cells than that of their Tazfl/fl littermates, 
but their YAP-deficient counterparts did not (Fig. 1d,e and data not 
shown). Moreover, Mst1−/− mice were prone to autoimmune diseases, 
such as Sjögren’s syndrome, with associated infiltration of the lacrimal 
gland by lymphocytic cells (Supplementary Fig. 1e). Consistent with 
that, real-time PCR analysis revealed substantially higher expression 
of Taz and TH17 signature genes in the lacrimal glands of Mst1−/− 
mice than in those of Mst1+/+ mice (Supplementary Fig. 1f). Notably, 
RORC (which encodes RORγt) and TAZ had higher coexpression in 
memory CD4+ T cells isolated from the peripheral blood of patients 
with rheumatoid arthritis or Sjögren’s syndrome disease than in that 
of healthy people (Fig. 1f,g and Supplementary Table 1). In addition, 
higher TAZ expression was also observed in human TH17 and Treg 
cells, but not in TH1 cells or TH2 cells, relative to its expression in TH0 
cells (Fig. 1h). Therefore, we speculated that TAZ might serve a criti-
cal role downstream of the kinases MST1 and MST2 in autoimmunity 
via regulation of the Treg cell and TH17 cell lineages.
TAZ is dispensable in T cell activation and proliferation
To further determine the function of TAZ in T cells, we analyzed mice 
with T cell–specific knockout of TAZ (Tazfl/flLck-Cre mice; called 
‘TAZ-cKO mice’ here). There were no gross differences between Tazfl/fl 
mice (called ‘wild-type mice’ here) and TAZ-cKO mice in their 
T cell subsets in the thymus, lymph nodes and spleen (Supplementary 
Fig. 2a–c). Moreover, peripheral CD4+ T cells in wild-type and 
TAZ-cKO mice showed similar expression of the activation markers 
CD62L (L-selectin) and CD44 (Supplementary Fig. 2b,d). Expression 
of the activation markers CD69, CD25, CD62L and CD44 on CD4+  
T cells, as well as production of the cytokines IL-2 and IFN-γ, were 
unaffected by the deletion of Taz when assessed after stimulation 
via the T cell antigen receptor (TCR) with antibody to the invariant 
signaling protein CD3 (anti-CD3) or with anti-CD3 plus antibody 
to the costimulatory receptor CD28 (anti-CD28) (Supplementary 
Fig. 2e,f). TAZ acts as a transcriptional co-activator of TEAD tran-
scription factors to promote cell proliferation. However, wild-type 
and TAZ-cKO CD4+ T cells, TH17 cells and Treg cells showed similar 
proliferation rates after stimulation with anti-CD3 plus anti-CD28 
(Supplementary Fig. 2g,h). Together these results indicated that the 
TCR-induced signaling cascade was intact in TAZ-deficient T cells 
and that TAZ was dispensable for the activation and proliferation of 
naive T cells.
TAZ drives TH17 differentiation but blocks Treg differentiation
To assess whether TAZ is involved in regulating commitment to the 
helper T cell lineage, we differentiated wild-type or TAZ-cKO naive 
CD4+ T cells under TH17-, Treg cell– or TH1-polarizing conditions. 
Notably, TAZ deficiency resulted in a significantly lower frequency of 
IL-17+ cells without affecting RORγt expression and a higher frequency of 
Foxp3+ cells, after TH17 skewing (Fig. 2a and Supplementary Fig. 2i,j). 
Knockout of TAZ also led to decreased expression of the cytokines IL-
17A, IL-17F and GM-CSF and the cytokine receptor IL-23R (Fig. 2a  
and Supplementary Fig. 2i,j). In addition, TAZ deficiency resulted 
in much greater frequency of Foxp3+ cells than that of wild-type 
Foxp3+ cells, after Treg cell skewing (Fig. 2b), and a frequency of IFN-γ+ 
cells and IFN-γ production comparable to that of wild-type and TAZ-
cKO naive CD4+ T cells, after TH1 skewing (Fig. 2c). Consistent 
with that, considerably fewer TH17 cells and many more Treg cells 
were present in the intestinal lamina propria (LP) of TAZ-cKO mice 
than in that of wild-type mice (Fig. 2d), which suggested that TAZ 
deficiency impaired the generation of TH17 cells and facilitated the dif-
ferentiation of Treg cells in vivo. Furthermore, overexpression of TAZ 
resulted in enhanced TH17 differentiation but attenuated Treg cell dif-
ferentiation, and reintroduction of TAZ into TAZ-cKO T cells ‘rescued’ 
the TAZ-deficient phenotypes (Fig. 2e). Thus TAZ had a critical role in 
balancing Foxp3 activity and RORγt activity during the development of 
TH17 cells and Treg cells.
TAZ-enhanced development of TH17 cell–driven autoimmunity
Next we sought to explore the role of TAZ in the development 
of TH17 cell–mediated inflammatory disease. We first immunized 
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Figure 1 The TH17 subset shows enrichment for TAZ, and TAZ is associated with TH17 cell–mediated autoimmune diseases. (a) Visualization and 
mapping (with the viSNE algorithm) of CD3+CD4+ T cells from the draining lymph nodes of KLH-treated Mst1fl/flMst2fl/fl and Mst1fl/flMst2fl/flOx40-Cre 
mice (above plots) analyzed by mass cytometry; colors indicate intensity of expression (key, right margin) of the markers IL-17 and Foxp3 (top left 
corners). Numbers in plots (bottom left corner) indicate percent TH7 cells (top row) or Treg cells (bottom row); red arrows indicate those subsets.  
(b) Expression of mRNA encoding components of the Hippo pathway (left margin) in various T cell subsets (above plot; two culture replicates per subset 
(one per column)) differentiated from naive CD4+ T cells in vitro; results were normalized (key) and are presented relative to those of TH0 cells, set as 1. 
(c) Immunoblot analysis (top) and real-time quantitative PCR (RT-qPCR) analysis (below) of TAZ expression in various mouse T cell subsets (above lanes 
(top) and horizontal axis (below)); GAPDH (above) serves as a loading control throughout, and RT-qPCR results are presented relative to those of the 
internal control gene Gapdh throughout. (d) Visualization of CD3+CD4+ T cells from the draining lymph nodes of KLH-treated Tazfl/fl and Tazfl/flLck-Cre 
mice (above plots) analyzed by mass cytometry (presented as in a). (e) Flow cytometry (left) and quantification (right) of intracellular IL-17, Foxp3 and 
IFN-γ in CD4+ T cells from the draining lymph nodes (LN) and spleen (left margin (left) and horizontal axis (right)) of KLH-treated Tazfl/fl or Tazfl/flLck-
Cre mice (n = 6 per genotype). Numbers in quadrants indicate percent cells in each throughout. (f,g) RT-qPCR analysis of TAZ and RORC mRNA (f) and 
correlation of the expression of TAZ with that of RORC (g) in memory CD4+ T cells isolated from peripheral blood of healthy donors (n = 18) and patients 
with rheumatoid arthritis (RA; n = 22) or Sjögren’s syndrome (SS; n = 21); results were plotted and analyzed with the linear-regression t-test (g).  
(h) RT-qPCR analysis of TAZ (left) and immunoblot analysis of TAZ (right) in various T cell subsets from healthy human donors (horizontal axis (left) and 
above lanes (right)). Each symbol (e–g) represents an individual mouse (e) or donor (f,g); small horizontal lines (e,f) indicate the mean (± s.e.m.).  
NS, not significant (P > 0.05); *P < 0.05, **P < 0.01 and ***P < 0.001, compared with TH0 (c,h) or as indicated by bracketing (Student’s t-test).  
Data are from one experiment representative of three independent experiments with similar results (a–e,h; mean + s.d. of n = 3 technical replicates 
(c,h) or n = 6 mice per genotype (e)) or one experiment (f,g).
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wild-type and TAZ-cKO mice with a myelin oligodendrocyte glyco-
protein (MOG) peptide of amino acids 35–55 to induce experimental 
autoimmune encephalomyelitis (EAE). TAZ-deficient mice exhibited a 
significantly lower incidence and severity of EAE than that of wild-type 
mice (Fig. 3a). Fewer CD3+ T cells and TH17 cells infiltrated the cen-
tral nerve system (CNS) of TAZ-cKO mice than that of wild-type mice 
at the onset or peak of EAE (Fig. 3b,c and Supplementary Fig. 2k,l). 
The number of Treg cells was also lower in TAZ-cKO mice than in wild-
type mice during EAE, but the ratio of Treg cells to TH17 cells among 
cells that infiltrated the CNS was higher in TAZ-cKO mice than in 
wild-type mice during EAE (Fig. 3b,d). In addition, a lower frequency 
of CD4+IL-17+ T cells, a higher frequency of CD4+Foxp3+ T cells and 
a similar frequency of CD4+IFN-γ+ T cells were present in the drain-
ing lymph nodes of TAZ-cKO mice relative to that in wild-type mice 
(Fig. 3e,f). TAZ-cKO T cells isolated from MOG-immunized mice 
showed impaired production of IL-17 but normal production of IFN-γ 
and IL-2 upon restimulation with the MOG peptide noted above 
(Fig. 3g). Furthermore, TAZ-deficient Treg cells exhibited a much 
greater ability to suppress the proliferation of naive CD4+ T cells and 
production of IL-2 than that of wild-type Treg cells (Supplementary 
Fig. 2m,n). Our result suggested that the TAZ-cKO mice were resistant 
to EAE owing to a defect in producing TH17 cells, as well as to enhanced 
induction and immunosuppressive function Treg cells.
We then obtained naive CD4+ T cells from mice with transgenic 
T cell–specific expression of Taz (TAZ-Tg mice) or TAZ-cKO mice, 
and from their non-transgenic or non-mutant control littermates, 
transferred the cells into host mice with a congenital deficiency in 
mature B cells and T cells (Rag1−/− mice) and tracked the development 
of colitis, another TH17 cell–driven autoimmune disorder, in the host 
mice. Adoptive transfer of TAZ-Tg T cells elicited more-severe weight 
loss and intestinal inflammation with a significantly greater frequency 
of TH17 cells in the colonic LP than that elicited by the transfer of 
control T cells (Fig. 3h–j). In contrast, host mice reconstituted with 
TAZ-cKO T cells developed much less severe disease with signifi-
cantly fewer TH17 cells in the colon LP than that of mice reconstituted 
with control T cells (Fig. 3k–m). Consistent with the in vitro assay, 
the development of IFN-γ-producing TH1 cells was not significantly 
affected in host mice given transfer of TAZ-Tg or TAZ-cKO T cells 
(Fig. 3j,m). These results indicated that TAZ probably promoted 
T cell–mediated colitis by enhancing TH17 differentiation.
To determine whether autoimmunity induced by MST1 deficiency 
disease relies on TAZ, we generated mice with double knockout of MST1 
and TAZ by crossing Mst1−/− mice with Tazfl/flLck-Cre mice (Mst1−/− 
Tazfl/flLck-Cre). Rag1−/− mice given adoptive transfer of Mst1−/− cells 
exhibited more severe intestinal inflammation than that of mice that 
received wild-type (Tazfl/fl) cells, while those that received Mst1−/−Tazfl/fl 
Lck-Cre cells showed less severe signs than those of mice that received 
wild-type cells (Fig. 3n,o). The frequency of TH17 cells, but not that of 
TH1 cells, was much lower in the LP of mice that received Mst1−/−Tazfl/fl 
Lck-Cre naive CD4+ T cells than in that of mice that received Mst1−/− 
or wild-type CD4+ T cells (Fig. 3m). Thus, MST1 deficiency resulted 
in autoimmune disease probably via activation of TAZ.
Smad3 and STAT3 synergistically upregulate Taz expression
TH17 differentiation is initiated by TGF-β and IL-6. We found that 
the abundance Taz mRNA was significantly increased by TGF-β alone 
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Figure 2 TAZ enhances TH17 cell differentiation but attenuates Treg cell differentiation in vitro. (a–c) Flow cytometry (left (a,b) and top (c)) and 
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Numbers adjacent to outlined areas (top) indicate percent IL-17A+CD4+ (TH17) cells (left) or Foxp3+CD4+ (Treg) cells (right). Each symbol represents 
an individual mouse; small horizontal lines indicate the mean (± s.d.). *P < 0.05, **P < 0.01 and ***P < 0.001, as indicated by bracketing (Student’s 
t-test). Data are representative of three independent experiments with similar results (a–c,e; cell cultures: n = 7 (a), n = 6 (b), n = 5 (c) or n = 3 (e)) or 
one experiment with n = 9 mice per genotype (d).
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Figure 3 TAZ potentiates TH17 cell–mediated autoimmune diseases. (a) Disease (EAE)-related behavioral scores of Tazfl/fl and Tazfl/flLck-Cre mice 
subjected to MOG-induced EAE (n = 6 per genotype). (b,c) Quantification (by flow cytometry) of CD4+IL-17+ and CD4+Foxp3+ cells that infiltrated 
the CNS of mice as in a at disease onset (b; n = 5 per genotype) or peak (c, n = 4 per genotype). (d) Ratio of TH17 cells (CD4+IL-17+) to Treg cells 
(CD4+Foxp3+) in the CNS of mice as in a. (e,f) CD4+IL-17+, CD4+Foxp3+ or CD4+ IFN-γ+ cells in the draining lymph nodes of mice as in a at disease 
onset (e; n = 3 per genotype) or peak (f; n = 3 per genotype). (g) ELISA of IL-17, IFN-γ and IL-2 in supernatants of cells obtained from the draining 
lymph nodes of mice as in a and left unstimulated (−) or stimulated for 2 d in vitro with MOG (n = 3 technical replicates). (h,k) Body weight of Rag1−/− 
recipient mice at various times (horizontal axes) after adoptive transfer (key) of no cells (Control) or 4 × 105 TAZ-Tg Cre− or TAZ-Tg naive CD4+ T cells 
(h; n = 7 host mice per group) or 4 × 105Tazfl/fl or Tazfl/flLck-Cre naive CD4+ T cells (k; n = 5 host mice per group), presented relative to initial body 
weight. (i,l) Microscopy of hematoxylin-and-eosin–stained colon sections of mice as in h (i) or k (l) at 9 weeks after cell transfer (above images); bottom 
row, enlargement of areas outlined in main images above. Scale bars, 200 µm. (j,m) Flow cytometry (left) and quantification (right) of CD4+IL-17+ and 
CD4+ IFN-γ+ cells in the colonic LP of mice given transfer of donor cells (left margin (left) or key (right)) as in i (j; n = 8 host mice per group) or l (m; 
n = 6 host mice per group). (n) Microscopy of hematoxylin-and-eosin–stained colon sections from Rag1−/− recipient mice after adoptive transfer of 4 × 
105Tazfl/fl, Mst1−/− or Mst1−/−Tazfl/flLck-Cre naive CD4+ T cells (above images). Scale bars, 200 µm. (o) Flow cytometry (left) and quantification (right) 
of CD4+IL-17+ and CD4+IFN-γ+ cells in the colonic LP of mice as in n (n = 3 per group). ND, not detectable. Each symbol (b–g,j,m,o) represents an 
individual mouse; small horizontal lines indicate the mean (± s.e.m.). *P < 0.05, **P < 0.01 and ***P < 0.001, Tazfl/fl versus Tazfl/flLck-Cre (a,k) or 
TAZ-Tg Cre− versus TAZ-Tg (h) or as indicated by bracketing (Student’s t-test). Data are representative of three independent experiments with similar 
results (mean ± s.e.m. in a,h,k).
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but not by IL-6 alone and that this increase was further enhanced 
by stimulation with a combination of TGF-β and IL-6 (Fig. 4a–c). 
Furthermore, treatment with an inhibitor of the TGF-β receptor 
TGF-βRII resulted in a reduction in the expression of Taz mRNA in 
a dose-dependent manner (Fig. 4d), which indicated that TGF-β was 
an essential factor in the induction of Taz expression.
To identify transcription factors that control Taz expression, we 
generated 2-kb biotinylated DNA fragments corresponding to Taz 
promoter sequences upstream of the ATG start codon and incubated 
them with mouse lymphoid tissue lysates, followed by a streptavidin-
precipitation assay. Several potential transcriptional factors, includ-
ing Smad3 and STAT3 (the main transcription factor downstream of 
signaling via TGF-β or IL-6), were identified by mass spectrometry 
(Supplementary Fig. 3). We found that knockdown of Smad3 or 
knockout of STAT3 significantly decreased TAZ expression in HeLa 
human cervical cancer cells or naive CD4+ T cells cultured under 
TH17-skewing conditions (Fig. 4e–g). Conversely, overexpression of 
Smad3 resulted in the induction of TAZ expression, and co-expression 
Smad3 with STAT3 further enhanced the TAZ expression (Fig. 4h,i). 
In addition, there are ten known Smad-binding sequences (GAG(A/C)C, 
where ‘(A/C)’ indicates either adenosine or cytosine) and ten STAT-
binding sequences (TT(N5)AA, where ‘(N5)’ indicates five nucle-
otides of any type) in the 2-kb region of the Taz promoter (Fig. 4j). 
Consistent with that, Smad3 increased the activity of the Taz  
promoter, but STAT3 did not, while Smad3 together with STAT3 syn-
ergistically enhanced this activity (Fig. 4k). Since the 1-kb and 2-kb 
Taz promoter regions have comparable activity, the essential binding 
sites of Smad3 or STAT3 for the transcription of Taz were probably 
located within the 1-kb promoter region. Direct binding of Smad3 
and STAT3 to the 1-kb promoter region was further confirmed by 
streptavidin-precipitation and chromatin-immunoprecipitation 
assays (Fig. 4l–n). Moreover, we measured and compared the activ-
ity of a luciferase reporter containing the Taz 1-kb promoter with 
individual mutated Smad-binding and/or STAT3-binding sites. We 
found that a Smad-binding site in the region −225 bp to −192 bp and a 
STAT3-binding site in the region of −282 bp to −240 bp (all positions 
relative to the transcription start site) were critical for Taz expres-
sion (Fig. 4o). Thus, we concluded that TGF-β–IL-6 signaling pro-
moted Taz expression through the downstream transcription factors 
Smad3 and STAT3.
TAZ directly activates RORγt’s transcriptional activity
We next sought to delineate the molecular mechanism underlying the 
promotion of TH17 cell development by TAZ. For this, we used anti-
Flag beads to immunoprecipitate proteins from lysates of lymphoid 
tissues from wild-type or TAZ-Tg mice in which Flag-tagged TAZ 
was overexpressed, then further analyzed the resultant immunopre-
cipitates by mass spectrometry. Notably, the components identified 
included known binding proteins of the TEAD family, as well as previ-
ously unknown binding partners, such as RORγt, Foxp3, Tip60 and 
others (Supplementary Fig. 4a). Furthermore, endogenous RORγt 
and Foxp3 were co-immunoprecipitated with TAZ in mixed lysates of 
TH17 cells and Treg cells (Supplementary Fig. 4b). To map the interac-
tion regions of TAZ and RORγt, we expressed green fluorescent pro-
tein (GFP)-tagged RORγt with a series of Flag-tagged truncated forms 
of TAZ, or vice versa, in 293T human embryonic kidney cells, followed 
by precipitation assays (Fig. 5a–d and Supplementary Fig. 4c,d). We 
found that the tryptophan-tryptophan (WW) domain of TAZ was 
essential for its interaction with RORγt, whereas the DNA-binding 
domain (DBD) and ligand-binding domain (LBD) of RORγt were 
responsible for its interaction with TAZ (Fig. 5e). The TAZ–RORγt 
interaction in the nucleus was further analyzed by a super-resolution 
immunofluorescence microscopy (SIM) approach. Notably, nuclear-
localization sequence (NLS)-tagged TAZ alone formed circular foci 
(probably a polymer of TAZ aggregates) in the nucleus, whereas full-
length or truncated fragments of RORγt alone were evenly distrib-
uted in the nucleus (Supplementary Fig. 4e). Consistent with the 
biochemical data, full-length RORγt and its DBD or LBD, but not 
its hinge portion, localized together with TAZ and formed circular 
foci (Fig. 5f). These data demonstrated that TAZ physically bound to 
RORγt in vitro and in vivo.
Moreover, the WW domain of TAZ interacted with the LBD of 
RORγt via the WW-domain-binding motif PPxY (Pro-Pro-x-Tyr, 
where ‘x’ indicates any amino acid) located in the carboxy-terminal 
activation-function region AF2 of RORγt. Mutant RORγt in which 
the amino acids Pro-Pro-Leu-Tyr of AF2 were replaced with Ala-Pro-
Leu-Ala failed to bind to TAZ (Fig. 5f,g). Since AF2 is the main tran-
scription-activation motif of RORγt, we speculated that TAZ might 
act as a co-activator of RORγt for the transcription of Il17a. Indeed, 
wild-type TAZ increased RORγt-mediated activity of the Il17a pro-
moter in a dose-dependent manner, but a truncated form of TAZ 
lacking the WW domain, which was unable to interact with RORγt, 
did not (Fig. 5h,i). Consistent with that, overexpression of wild-type 
TAZ in naive CD4+ T cells resulted in a significantly higher frequency 
of IL-17+ cells under TH17-skewing conditions, but overexpression of 
the truncated form of TAZ lacking the WW domain did not (Fig. 5j). 
Moreover, overexpression of TAZ in RORγt-deficient naive CD4+ T 
cells was unable to induce TH17 differentiation (Fig. 5k), which indi-
cated that RORγt was required for the TAZ-mediated development of 
TH17 cells. These results suggested that TAZ was a critical co-activator 
of RORγt for TH17 differentiation.
TAZ blocks Treg cell differentiation by inhibiting Foxp3
The developmental pathway for TH17 cells and that for Treg cells are 
reciprocally interconnected8. Notably, TAZ deficiency resulted in 
increased production of Foxp3 in T cells under both TH17-skewing 
conditions and Treg cell–skewing conditions (Fig. 6a). However, the 
abundance of Foxp3 mRNA was comparable in wild-type cells and 
TAZ-deficient cells (Supplementary Fig. 5a), which indicated that 
TAZ might regulate the stability of Foxp3 protein. Indeed, TAZ pro-
moted the degradation of Foxp3 protein, which was blocked by the 
proteasome inhibitor MG132 (Fig. 6b,c).
The acetylation of Foxp3 by the histone acetyltransferases Tip60 
and p300 is essential for inhibiting proteasomal degradation of Foxp3 
(ref. 43). Notably, TAZ-deficient Treg cells exhibited greater acetylation 
but less ubiquitination of endogenous Foxp3 than that of wild-type cells 
(Fig. 6d). Conversely, overexpression of TAZ attenuated the effect of 
Tip60 and p300 on the acetylation and stabilization of Foxp3 (Fig. 6e,f). 
In addition, we found that the coiled-coil domain of TAZ (residues 
158–249) interacted with the zinc domain of Tip60 (residues 113–283), 
while Foxp3 bound to the zinc-and-acetyltransferase-MYST domain of 
Tip60 (residues 113–513) (Supplementary Fig. 5b–d). These results 
suggested that TAZ might compete with Foxp3 to bind to the same 
motif between residues 113 and 283 of Tip60 (Fig. 6g). Indeed, co-
immunoprecipitation assays showed that TAZ exhibited higher affinity 
for Tip60 and efficiently disrupted the interaction between Tip60 and 
Foxp3 (Fig. 6h,i and Supplementary Fig. 5e). SIM further confirmed 
that the interaction of Foxp3 and Tip60 was abolished by TAZ (Fig. 6j 
and Supplementary Fig. 5f). Together these data indicated that TAZ 
impaired Treg cell development probably by sequestering Tip60 from 
Foxp3 and diminishing the Tip60-mediated acetylation of Foxp3 and 
targeting it for proteasomal degradation.
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TAZ activates RORγt by blocking Foxp3 activity
The data reported above established that TAZ negatively regulated the 
stability of Foxp3. We found that both RORγt and Foxp3 immuno-
precipitated together with TAZ (Supplementary Fig. 4a) and that the 
WW domain of TAZ was critical for its binding to RORγt (Fig. 5e). In 
addition, the WW domain of TAZ and the domain of Foxp3 consisting 
of amino acids 190–280 were essential for their interaction (Fig. 7a 
and Supplementary Fig. 6a–d). The LxxLL (Leu-x-x-Leu-Leu) motif 
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Figure 4 Smad proteins and STAT3 synergistically upregulate TAZ expression. (a–c) RT-qPCR analysis of Taz mRNA in naive CD4+ T cells cultured  
for 2, 3 or 4 d (horizontal axis) with anti-CD3 plus anti-CD28 alone (No cytokine) or together with TGF-β (2.5 ng/ml) or IL-6 (30 ng/ml) or both (key)  
(a) or for 3 d with anti-CD3 plus anti-CD28 together with a combination of IL-6 (+) or not (−) and various concentrations (below plot) of TGF-β (b) or 
TGF-β (+) or not (−) and various concentrations (below plot) of IL-6 (c); results are presented relative to those of Gapdh. (d) RT-qPCR analysis of Taz 
mRNA in naive CD4+ T cells cultured for 3 d as in a with various concentrations (below plot) of the TGF-βRII inhibitor (inh); results presented as in a–c.  
(e,f) Immunoblot analysis of Smad3 and TAZ (e) and RT-qPCR analysis of TAZ mRNA (f) in HeLa cells treated with control (non-targeting) short hairpin RNA 
(shRNA) (shCtrl) or either of two shRNAs (1, 2) targeting Smad3 (shSmad3); RT-qPCR results are presented relative to those ofGAPDH. (g) RT-qPCR 
analysis of Taz mRNA in Stat3fl/fl or Stat3fl/flLck-Cre naive CD4+ T cells (key) cultured for 3 d with anti-CD3 plus anti-CD28 without cytokines (−) or 
together with TGF-β (2.5 ng/ml) and IL-6 (30 ng/ml) (+). (h,i) Immunoblot analysis of TAZ, Smad3 and STAT3 (h) and RT-qPCR analysis of Taz mRNA  
(i) in naive CD4+ T cells infected with retrovirus expressing GFP alone (Vector) or GFP plus Smad3 or STAT3 or both (above lanes (h) or horizontal axis (i)).  
(j) Smad- and STAT-binding sites (key) in the Taz promoter region; numbers above diagram indicate position relative to the transcription start site (ATG; 
far right), and those below (with vertical lines) demarcate the 1-kb and 2-kb promoter regions. (k) Luciferase activity of 293T cells transfected with an 
empty luciferase reporter construct (pGL3-basic) or a construct containing the 1-kb or 2-kb Taz promoter (horizontal axis) and retrovirus as in h,i (key); 
firefly luciferase activity was normalized to that of Renilla, and results are presented relative to those of cells transfected with the empty luciferase 
construct and empty retroviral vector. (l) Streptavidin-precipitation (Strep ppt) assay (top) of 293T cells expressing various combinations (above lanes) of 
Myc-tagged Smad3 or Flag-tagged STAT3 and a biotinylated 1-kb Taz promoter, probed with anti-Myc (α-Myc) or anti-Flag (α-Flag) (right margin); below, 
input of total chromatin fragments (1% agarose (bottom) indicates Taz promoter DNA). (m,n) Chromatin immunoprecipitation of TH17 cells with the 
control antibody IgG or anti-Smad3 (m) or anti-STAT3 (n), followed by PCR with primers covering the Smad3- or STAT3-binding sequences from position 
−300 to position −100 of the Taz promoter; Input (far left lane), PCR as above without immunoprecipitation. (o) Luciferase activity (assessed as in k) of 
293T cells transfected with empty vector or plasmids expressing Smad3 and STAT3 (key) and with a luciferase reporter containing the 1-kb Taz promoter 
(left margin) with or without various deletions (‘X’). *P < 0.05, **P < 0.01 and ***P < 0.001, compared with cells cultured without cytokines or as 
indicated by bracketing (Student’s t-test). Data are representative of three independent experiments with similar results (mean + s.d. in a–d,f,g,i,k,o).
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Foxp3 and increasing doses (wedge; concentrations above lanes) of GFP-tagged TAZ. (c) Immunoblot analysis of the ubiquitination (Ub) of Foxp3 in 
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and mCherry-tagged Foxp3 (i), assessed in lysates after immunoprecipitation with anti-HA (h) or anti-Flag (i) (top group) or in total cell lysates without 
immunoprecipitation (below), probed with anti-HA or anti-Flag. (j) SIM of HeLa cells cotransfected to express various combinations of NLS- and Flag-
tagged TAZ (purple), GFP-tagged Foxp3 (green) and HA-tagged Tip60 (red) (insets as in Fig. 5f). Scale bars, 20 µm. Data are representative of three 
independent experiments with similar results (a–f) or with ~50 cells (j) or three experiments (h,i)). 
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located between residues 90 and 100 of Foxp3 is responsible for its 
interaction with RORγt43. RORγt failed to bind to a mutant Foxp3 in 
which the amino acid pair Leu-Leu in that motif was replaced with 
Ala-Ala (Foxp3(LL-AA)) (Fig. 7b,c). Those findings indicated that 
TAZ and RORγt bound to distinct regions of Foxp3, while Foxp3 and 
RORγt bound to the same site: the WW domain of TAZ. Notably, 
co-immunoprecipitation assays showed that Foxp3, RORγt and TAZ 
were able to form a complex (Fig. 7b,c and Supplementary Fig. 6d), 
which indicated that Foxp3 did not compete with RORγt for binding 
to TAZ. Moreover, in the presence of TAZ, RORγt was able to co-
precipitate wild-type Foxp3 and the mutant Foxp3(LL-AA) that was 
unable to bind to RORγt (Fig. 7b). Conversely, either wild-type Foxp3 
or Foxp3(LL-AA) was able to co-precipitate RORγt in the presence of 
TAZ (Fig. 7c), which indicated that TAZ might function as a scaffold to 
promote assembly of the Foxp3–TAZ–RORγt complex. Furthermore, 
SIM confirmed our findings (Fig. 7d and Supplementary Fig. 6e). 
These data suggested that TAZ might form a dimer or polymer 
to recruit Foxp3 and RORγt. TAZ polymerizes and forms foci 
through its motif for binding PDZ scaffolding structural domains10. 
Indeed, a truncated form of TAZ lacking the PDZ-binding motif 
impaired formation of the Foxp3(LL-AA)–TAZ–RORγt complex 
(Fig. 7e,f), which indicated that dimerized or polymerized TAZ 
was essential for assembly of the Foxp3–TAZ–RORγt complex 
(Supplementary Fig. 6f). Since Foxp3 can inhibit TH17 differen-
tiation by antagonizing the function of RORγt4, we speculated that 
TAZ might block the inhibitory effect of Foxp3 on RORγt. Indeed, 
co-expression of TAZ with Foxp3 and RORγt efficiently blocked the 
inhibitory effect of Foxp3 on RORγt activity (Fig. 7g). Together these 
results demonstrated that TAZ, RORγt and Foxp3 formed a complex 
in which TAZ blocked the inhibitory effect of Foxp3 on RORγt.
TEAD sequesters TAZ and inhibits TH17 development
MST1 and MST2 phosphorylate and activate the kinases LATS1 
and LATS2, which phosphorylate TAZ at Ser89; this results in its 
retention in the cytoplasm or proteasome-mediated degradation44. 
Once Hippo signaling is inactivated, dephosphorylated TAZ trans-
locates into the nucleus, where it binds to TEAD via residue Ser51 
(of TAZ) and activates TEAD45. Notably, overexpression of either 
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showing the domains involved (red arrows) and the Leu-x-x-Leu-Leu motif (LxxLL; top left); numbers above and below diagrams indicate amino acid 
range of each domain. (b) Immunoassay of 293T cells expressing various combinations (above lanes) of mCherry-tagged wild-type Foxp3 or Foxp3(LL-
AA), GFP-tagged TAZ and Flag-tagged RORγt, assessed anti-Flag immunoprecipitates (top group) or total cell lysates (below), probed with various 
antibodies (right margin). (c) Immunoassay (as in b) of 293T cells expressing various combinations of Flag-tagged wild-type Foxp3 or Foxp3(LL-AA), 
HA-tagged TAZ and GFP-tagged RORγt. (d) SIM of HeLa cells cotransfected to express (left margin) NLS- and Flag-tagged TAZ (purple), mCherry-tagged 
wild-type Foxp3 or Foxp3(LL-AA) (red) or GFP-tagged RORγt (green) (insets as in Fig. 5f). Scale bars, 20 µm. (e,f) Immunoassay (as in b) of 293T cells 
expressing various combinations (above lanes) of mCherry-tagged (e) or Flag-tagged (f) wild-type Foxp3 or Foxp3(LL-AA), Myc-tagged wild-type TAZ or 
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transfected with a luciferase reporter driven by the Il17a promoter and expressing vector alone (far left) or various combinations (horizontal axis) of 
TAZ, Foxp3 and RORγt (results presented as in Fig. 4k). *P < 0.01 and **P < 0.001 (Student’s t-test). Data are representative of three independent 
experiments with similar results (b–f) or with ~50 cells (d) or three experiments (g; mean + s.d. of n = 3 technical replicates).
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Figure 8 TEAD sequesters TAZ from RORγt to promote Treg cell development. (a) Flow cytometry (left) and quantification (right) of intracellular IL-17 in 
wild-type naive CD4+ T cells infected with empty retrovirus (Vector) or retrovirus expressing wild-type TAZ(WT), TAZ(S89A), TAZ(S51A) or TAZ(AA) (both 
substitutions) and differentiated under TH17-polarizing conditions. Numbers adjacent to outlined areas (left) indicate percent IL-17+CD4+ (TH17) cells. 
(b) Immunoblot analysis of TEAD1 or TEAD3 in total lysates of various T cell subsets (above lanes). (c) Immunoassay of 293T cells expressing various 
combinations (above lanes) of GFP-tagged RORγt or TAZ, HA-tagged TEAD and Flag-tagged Foxp3, assessed anti-Flag immunoprecipitates (top group) or total 
cell lysates (below), probed with various antibodies (right margin). (d,e) Immunoassay (as in c) of 293T cells expressing various combinations (above lanes) of 
GFP-tagged RORγt (d) or GFP-tagged Foxp3 (e) plus increasing doses (wedges) of GFP-tagged TEAD1, and Flag-tagged wild-type TAZ or TAZ(S51A). (f) SIM 
of HeLa cells with no expression of TAZ (Control) or cotransfected to express (left margin) NLS- and Flag-tagged wild-type TAZ or TAZ(S51A) (purple),  
HA-tagged TEAD1 (red) or GFP-tagged RORγt (green) (insets as in Fig. 5f). Scale bars, 20 µm. (g) Luciferase activity of 293T cells transfected with a luciferase 
reporter driven by the Il17a promoter and expressing empty vector (far left) or various combinations (horizontal axis) of wild-type TAZ, TAZ(S51A), TEAD1 
and RORγt (results presented as in Fig. 4k). (h) Immunoblot analysis of Foxp3, TAZ and TEAD1 in total lysates of 293T cells expressing various combinations 
(above lanes) of Flag-tagged Foxp3, GFP-tagged TAZ and increasing doses (wedge) of HA-tagged TEAD1. (i,j) Flow cytometry (left) and quantification (right) 
of Foxp3 in wild-type naive CD4+ T cells infected with a retrovirus expressing control shRNA (shCtrl) or shRNA targeting TEAD1 (shTEAD1) (above plots (left) 
or key (right)), differentiated under Treg cell–polarizing conditions (i), or of intracellular IL-17 in wild-type naive CD4+ T cells infected with empty retrovirus 
(Vector) or retrovirus expressing wild-type TEAD1 (WT) or TAZ-unbound TEAD1 (TEAD1(Y421A)) (above plots (left) or key (right)), differentiated under TH17-
polarizing conditions (j). Numbers in outlined areas (left) indicate percent Foxp3+CD4+ (Treg) cells (i) or IL-17+CD4+ (TH17) cells (j). Each symbol (a,i,j) 
represents an individual cell culture; small horizontal lines indicate the mean (± s.d.). *P < 0.05, **P < 0.01 and ***P < 0.001, as indicated by bracketing 
(Student’s t-test). Data are representative of three independent experiments with similar results (a–d,f–j; n = 4 cell cultures (a), n = 3 technical replicates (f),  
n = 4 (shCtrl) or 7 (shTEAD1) cell cultures (i) or n = 4 (Vector), 6 (WT) 4 (Y421A) cell cultures (j); error bars (g), s.d.) or with ~50 cells (e).
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a Hippo-refractory and active TAZ mutant, in which the serine at 
position 89 was replaced with alanine (TAZ(S89A)), or a TEAD-
binding-deficient TAZ mutant, in which the serine at position 51 
was replaced with alanine (TAZ(S51A)), significantly enhanced the 
induction of TH17 cells, and overexpression of a TAZ mutant with 
both substitutions induced a significantly greater frequency of IL-
17A+ cells than did overexpression of any other form of TAZ (Fig. 8a). 
These data indicated that both activation of Hippo signaling and the 
presence of TEAD proteins negatively regulated TAZ-mediated TH17 
differentiation. Notably, expression of TEAD1, TEAD2 and TEAD4 
was undetectable and expression of TEAD3 remained unchanged 
under Treg cell– or TH17-skewing conditions, while expression of 
TEAD1 was robustly induced under Treg cell–skewing conditions 
(Fig. 8b). Immunoprecipitation assays showed that TEAD1 had a 
higher affinity for TAZ than that of RORγt or Foxp3 and was able 
to disrupt the interaction of TAZ with RORγt or Foxp3 (Fig. 8c–e 
and Supplementary Fig. 7a,b). SIM further confirmed those find-
ings (Fig. 8f and Supplementary Fig. 7c). Moreover, TEAD1 sig-
nificantly decreased the TAZ- or RORγt-mediated activity of the 
Il17a promoter (Fig. 8g). Furthermore, TEAD1 sequestered TAZ 
from Tip60, which resulted in increased acetylation and stability of 
Foxp3 (Fig. 8h and Supplementary Fig. 7d,e). In addition, knock-
down of TEAD1 in naive CD4+ T cells resulted in decreased induction 
of Treg cells, while overexpression of TEAD1 resulted in diminished 
TH17 differentiation, but overexpression of a TAZ-unbound form 
of TEAD1 did not (Fig. 8i,j and Supplementary Fig. 7f). Give our 
results, we concluded that inactivation of Hippo signaling promoted 
translocation of TAZ nucleus, which was able to attenuate the func-
tion of Foxp3 and enhance RORγt-mediated TH17 development. On 
the other hand, high expression of TEAD1 sequestered TAZ from 
RORγt and Foxp3 to positively promote Treg cell differentiation 
(Supplementary Fig. 8).
DISCUSSION
In this study, we have revealed a physiological role for the transcrip-
tional co-activator TAZ in the maintenance of T cell homeostasis. 
Notably, expression of a transgene encoding TAZ or activation of 
TAZ via depletion of TAZ-inhibitory components of Hippo signal-
ing resulted in more TH17 cells and fewer Treg cells associated with 
autoimmune disease. Conversely, mice with TAZ-deficient T cells 
had more Treg cells and were more resistant to the induction of TH17 
cell–dependent inflammatory disease. Therefore, TAZ represents a 
key regulator at the branch point of commitment to the Treg cell line-
age or TH17 cell lineage that maintains immunotolerance. Both YAP 
and TAZ are homologous to Yorkie (Yki) in the Drosophila Hippo 
signaling pathway and act as co-activators of TEAD family of tran-
scription factors of the Hippo pathway to control cell growth in mam-
mals. However, we found that YAP expression in immune cells was 
very low, while TAZ expression was considerably induced during T 
cell differentiation. TAZ functioned as a co-activator of RORγt to 
promote TH17 differentiation. However, TEAD1 inhibited TH17 dif-
ferentiation and positively regulated the development of Treg cells by 
antagonizing the function of TAZ. Such data indicate distinct roles 
for TAZ and TEAD1 in commitment to the TH17 cell lineage or Treg 
cell lineage that are distinct from canonical Hippo signaling. Thus, 
it will be of particular interest to determine the expression, regula-
tion and function of transcription factors of the TEAD family in the 
development of Treg cells. Additionally, further work is needed to 
determine whether and which NDR kinases downstream of MST1 
and MST2, including NDR1, NDR2, LATS1 and LATS2, are involved 
in the regulation of TAZ during TH17 and Treg cell differentiation. 
Our current study has demonstrated that TAZ serves a vital role 
in TH17 differentiation through several possible mechanisms. The 
first was that TAZ directly bound and activated RORγt and blocked 
the inhibitory effect of Foxp3 on RORγt to increase the expression 
of TH17 signature genes and enhance TH17 development. Second, 
TAZ attenuated the development of Treg cells by diminishing Tip60-
mediated acetylation of Foxp3 and targeting it for proteasomal 
degradation. In addition to interacting with TEAD1, TAZ has been 
linked to interactions with other transcription factors, including 
RUNX2 (‘runt-related transcription factor 2’)46. Published studies 
have shown that RUNX1 can also promote TH17 differentiation 
through enhancing the expression and activation of RORγt47,48. It 
would be interesting to determine, in the future, the role of TAZ in 
Runx1-mediated TH17 differentiation. Although TAZ functions mainly 
as a transcriptional co-activator, studies have also shown that it serves 
as a transcriptional repressor of gene transcription dependent on the 
transcription factor PPARγ (‘peroxisome proliferator-activated 
receptor-γ’), including transcription of the gene encoding the inhibitory 
protein SOCS3 (ref. 9). SOCS3 negatively regulates IL-6 signaling49,50, 
which is critical for TH17 differentiation. Thus, it would be of 
interest to determine whether TAZ might promote IL-17 production 
via the repression of PPARγ-induced expression of SOCS3 or the 
activation of other transcription factors. MST1 deficiency in human 
and mice results in a complex combined immunodeficiency syn-
drome with autoimmune manifestations and recurrent bacterial and 
viral infections22,30. That observation is reinforced by our finding 
that TAZ enhanced the differentiation of inflammatory TH17 cells 
but attenuated the development of immunosuppressive Treg cells, 
which supports the likely physiopathological relevance of the Hippo 
signaling pathway it engages. Thus, we propose that TAZ represents 
a previously unknown therapeutic target of particular relevance to 
tolerance and inflammation.
METHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Animals. The conditional knockout of Mst1, Mst2, Taz and Yap1 has been 
previously described. Taz-transgenic mice were generated by Biocytogen 
(China). In brief, the pBS31-Taz plasmid was co-electroporated with a Flpe 
recombinase expression vector into ES cells that were expressing the M2rtTA 
tetracycline-responsive transactivator under control of the ROSA26 promoter. 
Transgene expression was induced by feeding the mice 2 mg/ml doxycycline 
in their drinking water supplemented with 10 mg/ml sucrose. For T cell– 
specific overexpression of TAZ, mice were crossed with mice expressing Cre 
under the control of the Lck promoter (Lck-Cre). Wild-type C57BL/6 mice, 
B6(Cg)-Rorctm3Litt/J mice (008771), Stat3tm1Xyfu mice (016923), Vav-Cre mice 
(008610), Lck-Cre mice (003802) and Ox40-Cre mice (012839) were originally 
from the Jackson Laboratory. Rag1−/− mice (B6.129S7-Rag1tm1/Nju) were pur-
chased from Nanjing Biomedical Research Institute of Nanjing University. All 
mice were maintained under specific-pathogen-free conditions at the Xiamen 
University Laboratory Animal Center. All mouse experiments were approved 
by the Institutional Animal Care and Use Committee and were in strict 
accordance with good animal practice as defined by the Xiamen University 
Laboratory Animal Center.
Chemicals and reagents. Trichostatin A (T1952), nicotinamide (72345), 
ionomycin (I0634), keyhole limpet hemocyanin (KLH, H7017), the phrobol 
ester PMA (P8139), DNase I (DN25) and MG132 (C2211) were from Sigma-
Aldrich. Golgi-Stop was from BD. Oligo nucleotides were synthesized by 
Sangon Biotech (Supplementary Table 2).
Patients and specimens. Human blood specimens were obtained with from 22 
subjects with rheumatoid arthritis, 21 subjects with Sjögren’s syndrome and 18 
healthy subjects at the First Affiliated Hospital of Xiamen University. Informed 
consent was provided by each subject before sample collection in accordance 
with the Declaration of Helsinki, and all procedures were approved by the 
ethics committee of Xiamen Health Science Center. Human memory CD4+ 
T cells were isolated with EasySep Human Memory CD4+ T Cell Enrichment 
Kit (StemCell Technologies).
KLH immunization. Mst1fl/flMst2fl/flOx40-Cre mice and Tazfl/flLck-Cre mice 
and their littermates (6–8 weeks old; three per group) were immunized at the 
base of the tail (100µl for each mouse) with KLH (0.5mg/ml) emulsified in 
complete Freund’s adjuvant (0.5mg/ml). 7 d later, cells of spleen or the draining 
lymph nodes from KLH-immunized mice were stimulated with PMA and ion-
omycin in the presence of GolgiStop for 4 h, followed by intracellular cytokine 
staining (antibodies identified below (‘Flow cytometry assays’)). Stained cells 
were analyzed with a BD LSRFortessa flow cytometer (BD Biosciences) or a 
CyTOF mass cytometer (Fluidigm).
T cell–transfer colitis model. Splenocytes were collected from 6- to 10-week-
old Tazfl/flLck-Cre, Taz Tg, Mst1−/−Tazfl/flLck-Cre or control mice, and naive 
CD4+ T-cells were isolated using a Naive CD4+ T Cell Isolation Kit. A total 
of 4 × 105 CD4+CD44−CD62L+CD25− cells were then adoptively transferred 
intraperitoneally into Rag1−/− mice that were subsequently weighed every 7 d to 
evaluate IBD development. Mice were killed at 8–10 weeks after transfer when 
substantial weight loss occurred in the control groups. Colonic specimens from 
distal colons were analyzed by histopathology. Tissues were harvested and fixed 
overnight in 10% neutral-buffered formalin and were embedded in paraffin for 
sectioning. Hematoxylin and eosin staining was performed on 5-µm paraffin 
sections according to common methods. Lymphocytes were isolated from spleen, 
mesenteric lymph nodes and colonic LP and analyzed by flow cytometry.
EAE mouse model. EAE disease was induced with a MOG peptide of amino 
acids 35–55 in complete Freund’s adjuvant. Mice were assigned scores daily 
on a scale of 0–5 in a double-blinded manner with the following criteria: 0, 
no disease; 1, tail paralysis; 2, wobbly gait; 3, hind limb paralysis; 4, forelimb 
paralysis; 5, moribund or dead. Gradations of 0.5 were assigned to mice exhib-
iting signs that fell between two of the scores listed above.
Isolation of lLP lymphocytes. Intestinal LP lymphocytes (LPLs) were pre-
pared as described below. The small intestine and colon were dissected, fat 
and Peyer’s patches were removed, and tissues were washed in PBS and cut 
into pieces. The intestinal pieces were then treated for 30 min at 37 °C with 
medium containing 100 g/ml dithiothreitol (Sigma), 25 mM Hepes, 10% FBS 
(FBS) and 5 mM EDTA in RPMI1640 medium to remove epithelial cells, and 
were washed extensively with RPMI1640. Tissues were further digested in 
RPMI1640 containing 2% FBS, collagenase D (400 U/ml, Roche) and DNase 
I (0.1 mg/ml, Sigma) in a shaking incubator at 37 °C for 30 min. Cells were 
then layered on a 40–75% Percoll gradient (GE Healthcare), and lymphocyte-
enriched populations were isolated from the cells at the 40%–75% interface 
after centrifugation at 2,000 r.p.m. for 20 min at room temperature. Lamina 
propria lymphocytes were washed twice, re-suspended in RPMI and used for 
further analysis.
Mass cytometry (CyTOF) assays. Single cells were washed and resuspended in 
Cell Staining Media (CSM; PBS with 0.5% BSA and 0.02% NaN3). The cells were 
incubated with cisplatin (479306; Sigma-Aldrich) at 5 µM at room temperature 
for 10 min and were washed three times with CSM. For surface-maker stain-
ing, cells were blocked with antibody to CD16/CD32 (101302; BioLegend) and 
were incubated for 30 min at room temperature with a metal-labeled antibody 
cocktail according to the manufacturer’s instructions, as follows: CD69-Nd143 
(3143004B), CD4-Nd145 (3145002B), CD8-Nd146 (3146003B), CD25-Eu151 
(3151007B), CD3e-Sm152 (3152004B), CD62L-Dy164 (3164003B), CD44-
Yb171 (3171003B) and B220-176Yb (3176002B) (all from Fluidigm); CXCR5-
148Nd (145502), CD138-154Sm (142502), GL-7-156Gd (144602), PD-1-159Tb 
(109113), IgD-Tm169 (405737) and CD150-170Er (115933) (all from Biolegend); 
and CD95-153Eu (14-0951-85 (from BD Bioscience); labeled with the indicated 
metal according to the manufacturer’s instructions (Fluidigm). For intracellular 
staining, the cells were fixed and permeabilized with Maxpar Nuclear Antigen 
Staining Buffer Set (201063, Fluidigm) at room temperature for 30 min, were 
washed and resuspended in Nuclear Antigen Staining Perm (1×) buffer, and then 
were stained for 30 min at room temperature according to the manufacturer’s 
instructions, as follows: IL-2-Nd144 (4144002B), Foxp3-Gd158 (3158003A), 
T-bet-Gd160 (3160010B), TNFa-DY162 (3162002B), IFN-g-Ho165 (3165003B), 
IL-4-Er166 (3166003B), IL-17A-174Yb (3174002B) (all from Fluidigm); and 
BCL-6-150Nd (648302) (from Biolegend); labeled with Nd according the manu-
facturer’s instructions (Fluidigm). After antibody staining, the cells were washed 
twice with CSM and then incubated for 10 min at room temperature (or overnight 
at 4 °C) with MAXPARNucleic Acid Intercalator-103Rh (DVS Sciences) in PBS 
with 1.6% formaldehyde. The cells were washed three times with CSM and once 
with PBS, diluted with water to ~1 × 106 cells per ml, and filtered through a 
40-µm membrane just before analysis by mass cytometry. Stained cells were then 
analyzed on a CyTOF mass cytometer (DVS Sciences) at an event rate of ~500 
cells per second. The settings of the instrument and the initial post-processing 
parameters were described previously51. All mass cytometry FCS files were 
uploaded and evaluated using Cytobank software and established methods52. 
For viSNE analysis, total cells were analyzed and equal cell numbers were sampled 
from each FCS file.
Flow cytometry assays. Single cells isolated from the spleen, lymph nodes 
or intestinal LP were stained for 20 min with the appropriate fluorescence- 
conjugated antibodies (identified below) and washed, then were resuspended 
with flow cytometry staining buffer (1% BSA in PBS) containing 4′,6-dia-
midino-2-phenylindole (DAPI; Invitrogen). For intracellular cytokine analysis, 
cells were re-stimulated with PMA (50 ng/ml) and ionomycin (1000 ng/ml) in 
the presence of Golgi-Stop (BD) for 4 h. Cells were then fixed and permeabi-
lized with Intracellular Fixation & Permeabilization Buffer Set (eBioscience), 
and stained with anti-IFN-γ, anti-IL-4, anti-IL-17A (identified below). For 
the expression of Foxp3, cells were treated with the Foxp3 Staining Buffer Set 
(eBioscience) and stained with anti-Foxp3 (identified below). Stained cells 
were analyzed with a BD LSRFortessa flow cytometer (BD Biosciences). Flow 
cytometry data were plotted and quantified with FlowJo software (TreeStar). 
The following antibodies were used: APC-conjugated anti-CD3ε (145-2C11, 
0.2 mg/ml, 1:50), PerCP-Cy5.5-conjugated anti-CD4 (RM4-5, 0.2 mg/ml, 
1:100), PE-Cy7-conjugated anti-CD4 (RM4-5, 0.2 mg/ml, 1:100), PerCP-
Cy5.5-conjugated anti-CD8 (53-6.7, 0.2 mg/ml, 1:100), FITC- conjugated anti-
CD44 (IM7, 0.5 mg/ml, 1:100), PE- or APC-conjugated anti-IFN-γ (XMG1.2, 
0.2 mg/ml, 1:100), PE-Cy7- or anti-IL17A (TC11-18H10.1, 0.2 mg/ml, 1:100), 
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PE-conjugated anti-IL-17F (9D3.1C8, 0.2 mg/ml 1:100), Alexa 488 -conjugated 
anti-Foxp3 (FJK-16S, 0.5 mg/ml, 1:200) and PE-Cy7-conjugated anti-IL-4 
(11B11, 0.2 mg/ml, 1:200), all from BioLegend; PE-conjugated anti-Foxp3 
(FJK-16S, 0.2 mg/ml, 1:100), APC-conjugated anti-CD25 (PC61.5, 0.2 mg/ml, 
1:100) and FITC-conjugated anti-B220 (RA3-6B2, 0.5 mg/mL, 1:100), all from 
eBioscience; and PE conjugated anti-CD62L (MEL14 ,0.2 mg/ml,1:100), from 
BD Bioscience.
Cell culture. The 293T and HeLa cell lines (from the American Type Culture 
Collection) were tested for mycoplasma contamination and were found 
to be negative for this. 293T and HeLa cell lines were cultured in DMEM 
supplemented with 10% FBS and 1× penicillin-streptomycin (Invitrogen). 
Lymphocytes were cultured in RPMI1640 complete medium with 10% FBS 
(Gibco), 1 mM sodium pyruvate (Gibco), 50 µM β-ME and 1× penicillin-
streptomycin (Invitrogen).
CFSE labeling. CD4+ cells were labeled for 8 min at 37 °C with 2.5 µM car-
boxyfluorescein diacetate succinimidyl ester (CFSE) according to the manu-
facturer’s instructions (Invitrogen), were washed three times with RPMI1640 
and were activated with plate-bound anti-CD3 (2 µg/ml; 100314, BioLegend) 
and anti-CD28 (2 µg/ml; 122004, BioLegend) in complete medium for 48 h, 
followed by flow cytometry.
Mouse T cell differentiation. Naive CD4+ T cells were prepared from the 
spleen and lymph nodes of mice using the Naive CD4+ T Cell Isolation 
Kit (130-104-453, Miltenyi Biotec) (purity was 97%). Cells were activated 
by plate-bound anti-CD3 (2 µg/ml; 100314; BioLegend) and anti-CD28 
(2 µg/ml; 122004; BioLegend) in the presence of TGF-β (2.5 ng/ml; 580706; 
BioLegend), IL-6 (30 ng/ml; AF-216-16; Peprotech), anti-IL-4 (10 µg/ml; 
504115; BioLegend) and anti-IFN-γ (10 µg/ml; 505827; BioLegend). For TH17 
polarization; TGF-β (2.5 ng/ml; 580706; BioLegend), for Treg cell polarization; 
IL-12 (10 ng/ml; 419-ML-050; R&D system) and anti-IL-4 (10 µg/ml; 504115; 
BioLegend), for TH1 polarization; or IL-4 (50 ng/ml; 404-ML-010; R&D sys-
tem), anti-IL-12 (10 µg/ml; 505305; BioLegend) and anti-IFN-γ (10 µg/ml; 
505827; BioLegend), for TH2 polarization.
Human T cell culture and differentiation. Mononuclear cells were prepared 
from the blood of healthy adult donors on Ficoll PAQUE gradients (GE). 
Human Naive CD4+ T cells were isolated with n EasySep Human Naive CD4+ 
T Cell Isolation Kit (Stemcell technologies). Cells were cultured in X-VIVO 
serum-free medium (Lonza) supplemented with gentamycin. CD4+ T cells were 
seeded at a density of 1 × 106 cells per ml in U-bottomed 96-well plates with pre-
coated with anti-CD3 (2 µg/ml; 300314, BioLegend) and anti-CD28 (2 µg/ml; 
302914, BioLegend) and were incubated at 4 °C overnight. For long-term 
experiments, cells were split as needed on day 3. For TH1 and TH2 cell dif-
ferentiation, ImmunoCult Human TH1 Differentiation Supplement and 
ImmunoCult Human TH2 Differentiation Supplement (Stemcell technolo-
gies) were added at day 0 and were maintained throughout the experiment. 
For Treg cell differentiation, IL-2 (10 U/ml, 100-12-10; Shenandoah), TGF-β1 
(2.5 ng/ml; 240-B-010; R&D Systems) and neutralizing antibodies to IL-4 
(1 µg/ml; 500815; BioLegend) and IFN-γ (1 µg/ml; 506513; Biolegend) were 
added at day 0 and were maintained throughout the experiment. For TH17 
differentiation, IL-1β (10 ng/ml; 201-LB-025; R&D Systems), IL-6 (10 ng/ml; 
206-IL-010; R&D Systems), IL-21 (10 ng/ml; 8879-IL-010; R&D Systems), 
IL-23 (10 ng/ml; 1290-IL-010; R&D Systems), TGF-β1 (2.5 ng/ml) and neu-
tralizing antibodies to IL-4 (1 µg/ml) and IFN-γ (1 µg/ml) were added at day 
0 and were maintained throughout the experiment. Cells were collected on 
day 6 for real-time PCR analysis and immunoblot analysis..
Regulatory T cell inhibition assays. CFSE labeled wild-type CD4+CD25− 
responder T cells (1 × 105) were cultured for 2–4 d in U-bottomed 96-well plates 
with control T cells (CD4+CD25−) or with Treg cells (CD4+CD25+), at various 
ratios, in the presence of soluble anti-CD3 (1 µg/ml; 100314; BioLegend) and 
4 × 105 irradiated (4,000 rads) splenocytes from wild-type mice were added to 
the co-culture as antigen-presenting cells instead of anti-CD28. Treg cells were 
isolated from spleen and lymph nodes of wild-type or TAZ-cKO mice using 
an EasySep Mouse CD4+CD25+ Regulatory T Cell Isolation Kit II (Stemcell 
technologies). Proliferation was assayed by CFSE dilution, and IL-2 production 
in culture was measured with ELISA kit.
Cytokine measurement. Cell supernatants were collected at the appropriate time 
points during culture. The concentrations of mouse IL-17, and IFN-γ were meas-
ured with ELISA kits (BioLegend) according to the manufacturer’s instructions.
Retroviral packaging and transduction. shRNA-containing oligonucleotides 
(TEAD1-specific and control shRNAs, Supplementary Table 1) were cloned 
into retroviral vector dLMP containing IRES-regulated GFP. Genes encoding 
wild-type TAZ, TAZ(S51A), TAZ(S89A) and TAZ(S89A,S51A) were cloned 
into retroviral vector pMIG containing IRES-regulated GFP, respectively. Plat-
E packaging cells were transfected with 3 µg of retroviral vector along with 
9 µl of TransIT-LT1 transfection reagent (Mirus). 48 h after transfection, the 
culture supernatant containing retrovirus was collected. Naive CD4+ T cells 
from wild-type or TAZ-cKO mice were activated with plate-bound anti-CD3 
and anti-CD28 in the presence or absence of 2.5 ng/ml TGF-β or 30 ng/ml 
IL-6 or combination of these stimuli. 24 h after stimulation, CD4+ T cells 
were infected with retrovirus together with 8 µg/ml polybrene and 100 U/ml 
IL-2 by centrifugation of cells at 2,000 r.p.m. for 60 min at room temperature. 
3 d after infection, the cells were re-stimulated with PMA and ionomycin in 
the presence of Golgi-Stop for 5 h, followed by intracellular cytokine staining 
(antibodies identified above) and flow cytometry analysis.
Lentivirus packaging and infection. Lentivirus was packaged by co- 
transfection in 293T cells with shRNA (Smad3-specific and control shRNAs, 
Supplementary Table 2) in the vector pll3.7, VSV-G and ∆8.9 plasmids by 
Lipofectamine 2000 (Invitrogen). Viral supernatants were harvested at 48h after 
transfection, then were passed through a 0.45-µm filter and diluted 2:3 with fresh 
medium containing 8 µg/ml polybrene and were used to infect the target cells at 
80% confluence. Protein expression was visualized by immunoblot analysis.
Transfection and luciferase reporter assay. Cells cultured in 12-well plates 
were transfected with the plasmids indicated in the main body of the text using 
Lipofectamine 2000 (Invitrogen). At 48 h after transfection, cells were washed 
with PBS and lysed in Reporter Lysis Buffer (Invitrogen). Luciferase reporter 
activities were measured in triplicate using the Dual-Luciferase reporter assay 
system (Promega, Madison, WI, USA), according to the manufacturer’s protocol, 
and quantified using the GloMax 96-well plate luminometer (Promega). The 
firefly luciferase to Renilla luciferase ratios were determined and were defined 
as the relative luciferase activity.
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) 
assays were performed according to the protocol of the CHIP assay kit 
(Upstate Biotechnology Inc., NY, USA) as previous described53. In brief, 
TH17 cells were fixed with 1% formaldehyde for 10 min at room temperature 
(RT) and then were quenched with glycine (125 mM) for 5min. The fixed 
cells were washed with PBS containing protease inhibitors and were lysed in 
lysis buffer (pH 8.1) containing 1% SDS, 10 mM EDTA, 50 mM Tris-HCl, 
and protease inhibitors, for 10 min on ice before the sonication, centrifuga-
tion and addition of dilution buffer. 1% of input was removed, and the lysates 
were immunoprecipitated with 10 µl of anti-Smad3 (5339S, CST), 10 µl of 
anti-Stat3 (9139, CST), or 2 µl of Normal Rabbit IgG (2729, CST) for 6 h. 
Salmon sperm DNA–protein A/G–Sepharose beads were added to the immu-
noprecipitation samples containing anti-Smad3, anti-STAT3 or IgG (control) 
for incubation overnight. Immunocomplexes were washed sequentially with 
low-salt buffer, high-salt buffer, LiCl buffer and twice with TE before elution 
in 200 ml of elution buffer (1% SDS, 0.1M NaHCO3). The elutes were heated 
at 65 °C for 4 h to reverse the cross-linking and were treated with RNase 
A for 30 min at 37 °C, followed by treatment with proteinase K for 1 h at 
45 °C, to remove RNA and protein. DNA was recovered using a QIAGEN PCR 
purification kit and was eluted in 50 ml of QIAGEN EB buffer (QIAGEN, 
Hilden, Germany). 1% of input and 10% of the immunoprecipitates were used 
in PCR analyses using AmpliTaq Gold DNA polymerase (Applied Biosystems, 
CA, USA) for 30 cycles at 95 °C for 30 s, 58 °C for 30 s, 72 °C for 60 s (after 
an initial denaturation for 10 min at 95 °C). The primers used for ChIP are 
in Supplementary Table 1.
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Ubiquitination assay. 293T cells were transfected for 36 h with the appropriate 
plasmids and were lysed in ice-cold lysis buffer (‘TNTE 0.5%’: 50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1 mM EDTA and 0.5% Triton X-100, containing 10 mM 
NaF, 2 mM Na3VO4, 10 mg/ml leupeptin and 1 mM PMSF). The cell lysates 
were subjected to immunoprecipitation with anti-Flag (identified below), were 
eluted by boiling 10 min in 1% SDS, were diluted ten times in lysis buffer TNTE 
0.5% and then underwent re-immunoprecipitation with anti-Flag (2 × IP). The 
ubiquitin-conjugated proteins were detected by immunoblot analysis with 
the appropriate antibodies (identified below).
Immunoblot analysis. Cells were lysed in cell lysis buffer containing 150 mM 
NaCl, 0.1 mM EDTA, 5% glycerol, 10% Triton-100, 10 mM and a ‘cocktail’ 
of protease inhibitors. Proteins were separated by SDS-PAGE, transferred 
onto a PVDF membrane and then identified by immunoblot analysis with 
the appropriate primary antibodies at a dilution of 1:1,000 (or as stated 
otherwise below). anti-phosphorylated Stat3 (9145), anti-phosphorylated 
Smad3 (9520), anti-STAT3 (9139), anti-Smad3 (9523), anti-ubiquitin (3936), 
anti-ubiquitinK48 (8081), anti-GAPDH (5174), anti-TAZ (4883) and anti-
DYKDDDDK (14793), all from Cell Signaling Technology; anti-HA (sc-7392, 
sc-805), anti-GFP (sc-8334), anti-Octa (sc-166355), anti-Foxp3 (sc-28705), 
anti-RORγt (sc-14196) and anti-Myc (sc-40), all from Santa Cruz; anti-K-
Ace (#05-515), from Millpore; anti-KAT5 (10827-1-AP), from Proteintech; 
and horseradish peroxidase–conjugated antibody to rabbit IgG (7074) or to 
mouse IgG (7076) (1:3,000 dilution for each), from Jackson ImmunoResearch 
Laboratories. The protein bands were visualized with a SuperSignal West 
Pico Kit according to the manufacturer’s instructions (Thermo Fisher 
Scientific Pierce).
Confocal fluorescence microscopy. HeLa cells seeded on cover slips in six-
well dish with 30% confluence were transfected with the appropriate con-
structs and were cultured for another 24 h. The cells were washed three times 
with PBS and were fixed for 15 min at room temperature with 4% (vol/vol) 
paraformaldehyde, after which additional immunofluorescence staining was 
applied. For staining with anti–DYKDDDDK (Flag) tag (1:250 dilution; 14793; 
CST) or anti–HA tag (1:250 dilution; sc-7392; Santa Cruz), then fixed cells 
were rinsed with PBS and then incubated for 10 min on ice with 0.2% Triton 
X-100 and 0.2% BSA in PBS. Following permeabilization, nonspecific binding 
in the cells was blocked by incubation for 30 min at room temperature with 
0.02% Triton X-100 and 5% BSA in PBS and cells were incubated for 3 h with 
specific primary antibodies (identified above). After three washes with PBS, 
the cells were incubated for another 1 h with secondary antibodies (1:250, 
Alexa Fluor 555–conjugated anti–mouse IgG (A31570) or Alexa Fluor 647– 
conjugated anti–rabbit IgG (A21246); both from Invitrogen). Subsequently, the 
cells were washed three times with PBS and were mounted with Vectashield 
mounting medium containing DAPI. All images were collected with a Precision 
DeltaVision-OMX Super-Resolution Microscope (GE OMX V4).
Mass spectrometry. After staining of gels with Coomassie blue, excised gel 
segments were subjected to in-gel trypsin digestion and dried. Peptides were 
dissolved in 10 µl 0.1% formic acid and were auto-sampled directly onto a 
100-µm × 10-cm fused silica emitter made in-house and packed with reversed-
phase ReproSil-PurC18-AQ resin (3 µm and 120 Å; Ammerbuch). Samples 
were then eluted for 60 min with linear gradients of 5–32% acetonitrile in 
0.1% formic acid at a flow rate of 300 nl/min. Mass spectra data were acquired 
with a TripleTOF 5600+ mass spectrometer (AB Sciex) equipped with a nano-
electrospray ion source. Data were collected at an IDA mode. The wiff files 
were searched with the ProteinPilot (Version 4.5) against a database from the 
Uniprot protein sequence database.
Quantitative real-time PCR. Following isolation with TRIzol reagent 
(Invitrogen), mRNA was specifically purified with a RNAeasy Mini Kit 
(Qiagen). First-strand cDNA was then obtained with the PrimeScript RT 
reagent Kit with gDNA Eraser (Takara). Real-time quantitative PCR was 
performed using SYBR Premix Ex TaqII (Takara) and the Bio-Rad iCycler 
iQ system (Bio-Rad, Hercules, CA, USA). All runs were accompanied by the 
internal control gene Gapdh. The samples were run in triplicate and nor-
malized to GAPDH using a ∆∆ cycle threshold-based algorithm, to provide 
arbitrary units representing relative expression levels. The primer sequences 
for specific genes are in Supplementary Table 2.
Statistical analysis. All statistical analyses were performed with Prism5 software 
(GraphPad Software). Student’s t-test was used for comparisons between two 
groups. The relative expression levels of RORC and TAZ in memory CD4+ T cells 
isolated from blood of patients were plotted, and the linear regression t-test was 
applied. A P value of less than 0.05 was considered statistically significant.
Data availability. The data that support the findings of this study are available 
from the corresponding author upon request.
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